Inside information: Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America

About this update from Fagron Sa

[{"type":"image","alt":"Fagron NV","displaySize":"","headline":null,"caption":"Fagron NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/01507f83c8cd7cebb0a99a82c723a556"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TBfMLlZobaCODCfSBVX7eQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/01507f83c8cd7cebb0a99a82c723a556","width":300,"height":108}},"lazy":false},{"type":"text","content":"Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 January 2026 – 7:00 AM CET","length":120,"tagName":"p"},{"type":"text","content":"Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America","length":102,"tagName":"p"},{"type":"text","content":"Fagron, the leading global player in pharmaceutical compounding, is pleased to announce the completion of University Compounding Pharmacy (UCP), a 503A pharmaceutical compounder focused on the health and wellness segment in California. The transaction was previously announced in September 2025 and has now closed following customary clearance.","length":344,"tagName":"p"},{"type":"text","content":"UCP is based in San Diego and has strong positions in hormones and urology, alongside a solid compliance record. The business is highly complementary to Anazao and supports Fagron’s strategy to build a nationwide platform in the United States, spanning both 503A (patient specific) and 503B (outsourcing) services.","length":314,"tagName":"p"},{"type":"text","content":"The acquisition also strengthens Fagron’s position in California, one of the largest and most tightly regulated healthcare markets in the United States, where licenses are difficult to obtain.","length":192,"tagName":"p"},{"type":"text","content":"As previously disclosed, the enterprise value of the acquisition is c.$41.5 million, with annual revenues of around $25 million and an EBITDA margin below Fagron’s existing group margin. Fagron expects to realise synergies over the next 18 to 24 months as the business is integrated into its operations.","length":303,"tagName":"p"},{"type":"text","content":"Over recent months, Fagron has executed fourteen acquisitions across all regions, with selective expansion into Asia-Pacific. Injeplast, MagiLab, Vepa...

More updates from Fagron Sa